PharmEnable is a drug discovery company using a combination of medicinal chemistry and AI computational approaches to design the next generation of small molecule drugs. Their approach focuses on efficiently mapping the possible chemical space to design complex, 3-dimensional small molecules, inspired by nature. PharmEnable is a spin-out company from the Department of Chemistry in the University of Cambridge, encompassing over two decades of research into diversity-oriented synthesis and world-leading expertise in computational chemistry. During the 2020 UK lockdown, the company secured 1.8 million GBP in seed financing led by Cambridge Enterprise alongside angel investors and life science investment funds.